Evaluating QbD's Impact on the Outsourced Relationship - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating QbD's Impact on the Outsourced Relationship
An Industry Roundtable Moderated by Patricia Van Arnum and Rich Whitworh. Contract service and technology providers share their perspectives on the influence of quality by design in the expectations between sponsor companies and outsourcing providers.

Pharmaceutical Technology
Volume 35, pp. s18-s24

QbD at work

PharmTech : Do you have an example from your own work in which QbD came into play as part of an outsourcing project?

McQuaid (Almac): We have examples where clients have asked us to develop their 'to-be-marketed' formulations. It has been clear from the start of some projects that a QbD approach was desired, so formulation development, analytical development, and process scale-up were all conducted using risk assessment and DoE processes.

Herring (DSM): We are in the final phase (NDA submission) of a QbD project for a new customer in which we provided full formulation, finish dosage, and scale-up activities for a new molecule. The QbD activity was very successful for our customer. We collaborated to identify critical quality characteristics as well as critical process parameters, conducted multivariate analysis, and established in-process specifications to ensure robustness during manufacturing as well as all requirements for the NDA filing.

Lewis (IRIX) : IRIX provided development and manufacturing services for a project using QbD principles to develop and assess risk for manufacturing of a Phase III development API. In preparation for a registration campaign, a two batch demonstration campaign was planned. Prior to the demonstration campaign, IRIX conducted a proven acceptable range (PAR) study for optimization of a hydrogenation step using a new catalyst identified through screening by the catalyst manufacturer. The PAR study compared the process performance of the new catalyst in reaction conditions designed to model the manufacturing process and equipment while using the previous catalyst as a control. IRIX also worked with the client to conduct studies using failure mode and effects analysis (FMEA) of each process step and to incorporate recommendations from those studies in the batch records for the demonstration campaign. A further set of FMEA studies will be conducted prior to the registration campaign using the data collected during the demonstration campaign as well as continued research and development laboratory studies into key areas of concern relative to process control and economics.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here